| Literature DB >> 26062128 |
Gloria Castellano1, Francisco Torrens2.
Abstract
Seventeen isoflavonoids from isoflavone, isoflavanone and isoflavan classes are selected from Dalbergia parviflora. The ChEMBL database is representative from these molecules, most of which result highly drug-like. Binary rules appear risky for the selection of compounds with high antioxidant capacity in complementary xanthine/xanthine oxidase, ORAC, and DPPH model assays. Isoflavonoid structure-activity analysis shows the most important properties (log P, log D, pKa, QED, PSA, NH + OH ≈ HBD, N + O ≈ HBA). Some descriptors (PSA, HBD) are detected as more important than others (size measure Mw, HBA). Linear and nonlinear models of antioxidant potency are obtained. Weak nonlinear relationships appear between log P, etc. and antioxidant activity. The different capacity trends for the three complementary assays are explained. Isoflavonoids potency depends on the chemical form that determines their solubility. Results from isoflavonoids analysis will be useful for activity prediction of new sets of flavones and to design drugs with antioxidant capacity, which will prove beneficial for health with implications for antiageing therapy.Entities:
Keywords: ADMET; QSAR; absorption; antioxidant; poor absorption or permeation; structure-activity relationship
Mesh:
Substances:
Year: 2015 PMID: 26062128 PMCID: PMC4490477 DOI: 10.3390/ijms160612891
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Molecular structure of isoflavonoids from Dalbergia parviflora.
|
|
|
|
|
|
|
|
|
|
| 1 | Khrinone C | OH | OH | OMe | OH | OMe | H | |
| 2 | Calycosin | H | OH | H | OH | OMe | H | |
| 3 | Genistein | OH | OH | H | H | OH | H | |
| 4 | 3′- | OH | OH | H | OMe | OH | H | |
| 5 | Cajanin | OH | OMe | OH | H | OH | H | |
| 6 | Khrinone B | OH | OH | OH | H | OMe | OH | |
| 7 | Biochanin A | OH | OH | H | H | OMe | H | |
| 8 | Formononetin | H | OH | H | H | OMe | H | |
|
|
|
|
|
|
|
|
|
|
| 9 | 3( | H | OH | OMe | OH | OMe | H | |
| 10 | 3( | OH | OH | OMe | OH | OMe | H | |
| 11 | 3( | H | OH | OMe | H | OMe | OH | |
| 12 | 3( | H | OH | OMe | H | OCH2O | ||
| 13 | 3( | H | OH | OMe | H | OMe | H | |
| 14 | 3( | H | OH | OMe | OMe | OMe | H | |
|
|
|
|
|
|
|
|
|
|
| 15 | 3( | OH | H | OH | H | OMe | H | |
| 16 | 3( | OH | H | OMe | OH | OMe | H | |
| 17 | 3( | OH | OH | OMe | OH | OMe | H | |
Antioxidant activity (X/XO, ORAC, DPPH assays) of isoflavonoids from D. parviflora and ChEMBL physico/physiochemical descriptors.
| Entry | X/XO Assay SC50 [μM] a | ORAC Assay TE [μM] b | DPPH Assay SC50 [μM] a | Log X/XO | Log ORAC | ALog
| ACD Log
| ACD Log
| ACD p | RBN h | QEDw i | PSA [Å2] j | NH + OH | HBD k | N + O | HBA l | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 0.64 | 43.5 | 61.7 | −0.194 | 1.638 | 330 | 2.11 | 2.25 | 0.82 | 6.32 | 3 | 0.79 | 105 | 3 | 3 | 7 | 7 |
| 2 | 0.25 | 37.8 | 96.2 | −0.602 | 1.577 | 284 | 2.37 | 1.33 | 0.75 | 6.95 | 2 | 0.89 | 76 | 2 | 2 | 5 | 5 |
| 3 | 9.0 | 37.8 | 300 | 0.954 | 1.577 | 270 | 2.14 | 3.11 | 1.93 | 6.51 | 1 | 0.74 | 87 | 3 | 3 | 5 | 5 |
| 4 | 36.7 | 35.7 | 81.2 | 1.565 | 1.553 | 300 | 2.12 | 2.63 | 1.25 | 6.35 | 2 | 0.79 | 96.2 | 3 | 3 | 6 | 6 |
| 5 | 54.3 | 34.7 | 70.8 | 1.735 | 1.540 | 369 | 3.52 | 3.88 | 3.86 | 8.93 | 8 | 0.54 | 96.2 | 3 | 3 | 6 | 6 |
| 6 | 0.60 | 34.2 | 133.6 | −0.222 | 1.534 | 316 | 1.88 | 1.71 | 0.37 | 6.38 | 2 | 0.63 | 116 | 4 | 4 | 7 | 7 |
| 7 | 203.3 | 26.6 | 300 | 2.308 | 1.425 | 284 | 2.37 | 3.34 | 2.11 | 6.5 | 2 | 0.89 | 76 | 2 | 2 | 5 | 5 |
| 8 | 116.92 | 2.8 | 300 | 2.068 | 0.447 | 268 | 2.61 | 6.99 | 2.86 | 2.31 | 2 | 0.91 | 55.8 | 1 | 1 | 4 | 4 |
| 9 | 43.7 | 31.1 | 89.7 | 1.640 | 1.493 | 286 | 2.48 | 7.69 | 2.63 | 2.44 | 2 | 0.89 | 76 | 2 | 2 | 6 | 5 |
| 10 | 247.2 | 27.4 | 74.3 | 2.393 | 1.438 | 302 | 2.24 | 2.76 | 2.34 | 7.5 | 2 | 0.79 | 96.2 | 3 | 3 | 7 | 6 |
| 11 | 48.2 | 21.8 | 80.4 | 1.683 | 1.338 | 332 | 2.22 | 7.48 | 3.01 | 2.58 | 3 | 0.79 | 105 | 2 | 3 | 6 | 7 |
| 12 | 56.9 | 0.0 | 300 | 1.755 | 0.0 | 330 | 2.25 | 4.52 | 4.1 | 7.48 | 2 | 0.87 | 94.4 | 1 | 2 | 6 | 7 |
| 13 | 59.3 | 0.0 | 300 | 1.773 | 0.0 | 270 | 2.72 | 3.48 | 3.31 | 7.7 | 2 | 0.91 | 55.8 | 1 | 1 | 5 | 4 |
| 14 | 300 | 0.0 | 300 | 2.477 | 0.0 | 330 | 2.69 | 2.93 | 2.74 | 7.67 | 7 | 0.93 | 74.2 | 1 | 1 | 6 | 6 |
| 15 | 6.4 | 40.1 | 204.1 | 0.806 | 1.603 | 272 | 3.2 | 3.26 | 3.25 | 9.53 | 2 | 0.88 | 58.9 | 2 | 2 | 4 | 4 |
| 16 | 10.0 | 39.8 | 75.41 | 1.000 | 1.600 | 302 | 3.18 | 2.84 | 2.84 | 9.87 | 3 | 0.91 | 68.2 | 2 | 2 | 5 | 5 |
| 17 | 13.4 | 27.0 | 115.4 | 1.127 | 1.431 | 318 | 2.94 | 1.65 | 1.65 | 9.75 | 3 | 0.75 | 88.4 | 3 | 3 | 6 | 6 |
a SC50: concentration providing 50% inhibition; b Expressed as Trolox equivalents (TE, μM Trolox)/10 μM isoflavonoid; c Mw: molecular weight; d ALog P: decimal logarithm of the 1-octanol-water partition coefficient (log P) calculated by the method ALog P; e ACD Log P: log P calculated by ACD/Log P; f ACD Log D: decimal logarithm of the 1-octanol-water distribution coefficient (log D) calculated by ACD/Log D at pH 7.4; g ACD Acidic pKa: pKa calculated by ACD/pKa; h RBN: rotatable bonds; i QEDw: weighted quantitative estimate of drug-likeness; j PSA: topological polar surface area; k HBD: hydrogen-bond donor; l HBA: hydrogen-bond acceptor.
Cross-validation correlation coefficient in a leave-m-out procedure for isoflavonoids.
| −Log X/XO Equation (3) | −Log X/XO Equation (4) | Log ORAC Equation (5) | Log ORAC Equation (6) | −DPPH Equation (7) | −DPPH Equation (8) | DPPH Equation (11) | DPPH Equation (12) | ALog
| |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 0.553 | 0.726 | 0.758 | 0.870 | 0.400 | 0.655 | 0.638 | 0.748 | 0.824 |
| 2 | 0.552 | 0.725 | 0.757 | 0.870 | 0.405 | 0.653 | 0.638 | 0.748 | 0.828 |
| 3 | 0.550 | 0.724 | 0.756 | 0.869 | 0.409 | 0.651 | 0.638 | 0.747 | 0.832 |
| 4 | 0.549 | 0.722 | 0.755 | 0.867 | 0.415 | 0.648 | 0.638 | 0.746 | 0.836 |
| 5 | 0.546 | 0.720 | 0.753 | - | 0.422 | 0.645 | 0.637 | 0.745 | 0.839 |
| 6 | 0.544 | 0.717 | 0.751 | - | 0.431 | 0.641 | 0.637 | 0.744 | - |
| 7 | 0.540 | 0.713 | 0.749 | - | 0.442 | 0.636 | 0.635 | 0.743 | - |
| 8 | 0.537 | 0.707 | 0.746 | - | - | - | 0.633 | 0.742 | - |
| 9 | 0.532 | 0.698 | - | - | - | - | 0.629 | 0.741 | - |
| 10 | 0.527 | 0.682 | - | - | - | - | 0.624 | 0.740 | - |
| 11 | 0.521 | 0.650 | - | - | - | - | 0.615 | 0.741 | - |
| 12 | 0.516 | - | - | - | - | - | 0.600 | - | - |
| 13 | 0.509 | - | - | - | - | - | 0.565 | - | - |
| 14 | 0.436 | - | - | - | - | - | - | - | - |
Summary of physicochemical and physiochemical descriptors selected for every property.
| Property | CLog
| RBN c | QEDw d | N + O | CLog
| NH + OH | PSA [Å2] e | HBD f | HBA g | Others | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tractability | 200–800 i | ≤8 i | ≤16 | >0.2 | ≤16 | >−8 | ≤8 | ≤140 | ≤8 | ≤15 | No metal, sugar, carbohydrates |
| Drug-likeness | 100–500 i | ≤5 i | ≤10 | >0.5 | ≤10 | >−5 | ≤5 | ≤105 | ≤5 | ≤10 | No metal, sugar, carbohydrates |
| Stringent drug-likeness | 100–450 i | ≤4 i | ≤10 | >0.5 | ≤8–9 | >−4.5 | ≤3 | ≤105 | ≤3 | ≤8–9 | No metal, sugar, carbohydrates |
| CNS-active h | 100–400 | ≤3.5 i,j | ≤7 | >0.7 | ≤5 | >0 | ≤4 | ≤70j | ≤4 | ≤5 | No metal, sugar, carbohydrates |
a Mw: molecular weight; b CLog P: decimal logarithm of 1-octanol-water partition coefficient (log P) calculated by CLog P; c RBN: rotatable bonds; d QEDw: weighted quantitative estimate of drug-likeness; e PSA: topological polar surface area; f HBD: hydrogen-bond donor; g HBA: hydrogen-bond acceptor; h Central nervous system (CNS)-active: penetrating the blood-brain barrier (BBB); i Mw > 400 Da when CLog P > 4 carries toxicity risk; j CLog P > 3 when PSA < 75 Å2 carries toxicity and promiscuity risks.